ArticleTransplantation2025
Progressive Hyperglycemia in Tolerant Miniature Swine Recipients of Composite Islet-kidney Grafts Is not due to Islet Loss but Rather to Increased Insulin Demand With Growth.
Article in Transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundIntraportal pancreatic islet transplantation could potentially provide a cure for type 1 diabetes, but this procedure usually requires >1 infusion along with loss of function with time posttransplant. We have previously demonstrated in a major histocompatibility complex (MHC) inbred miniature swine large animal model that the construction of an "islet-kidney" (IK) by implantation of autologous donor islets under the kidney capsule several weeks before transplantation reduces the extent of islet loss. The long-term islet function in juvenile recipients, tolerant to allogeneic IKs, is evaluated in this study.
methodsWe transplanted IKs across minor (n = 3) and full MHC (n = 1) mismatches, using a tolerance-inducing regimen consisting of 12-d treatment with either cyclosporine A or FK506. All 4 recipients experienced an increase in their body mass over time and this weight gain coincided significantly ( P < 0.01) with the development of hyperglycemia. To test the hypothesis that the hyperglycemia in these recipients might be due to increased body mass rather than islet loss, the grafts were subsequently retransplanted into MHC-matched, diabetic miniature swine, similar in weight to the original recipients, using the same tolerance-inducing regimen.
resultsAll 4 of the secondary graft recipients regained glycemic control initially, with a similar, significant correlation between body weight and fasting blood glucose ( P < 0.001) over time.
conclusionsThese findings indicate that loss of function of a vascularized IK graft with time is likely due to increased insulin demand in a growing animal and not due to islet loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.